Toll Free: 1-888-928-9744

Molecular Partners AG - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Molecular Partners AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Molecular Partners AG - Product Pipeline Review - 2014', provides an overview of the Molecular Partners AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Molecular Partners AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Molecular Partners AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Molecular Partners AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Molecular Partners AG's pipeline products

Reasons to buy

- Evaluate Molecular Partners AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Molecular Partners AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Molecular Partners AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Molecular Partners AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Molecular Partners AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Molecular Partners AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Molecular Partners AG Snapshot 5
Molecular Partners AG Overview 5
Key Information 5
Key Facts 5
Molecular Partners AG - Research and Development Overview 6
Key Therapeutic Areas 6
Molecular Partners AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Molecular Partners AG - Pipeline Products Glance 12
Molecular Partners AG - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Molecular Partners AG - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Molecular Partners AG - Drug Profiles 15
MP-0250 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
MP-0210 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
MP-0274 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Recombinant Proteins for Auto-Immune Diseases and Inflammation 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Anti-IgE DARPin-Fc Fusion Protein 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MP-0270 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Recombinant Protein for Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Recombinant Protein for Cardiovascular Diseases 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Recombinant Protein for Central Nervous System Disorders 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Recombinant Protein for Infectious Diseases 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Recombinant Protein for Metabolic Diseases 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Molecular Partners AG - Pipeline Analysis 26
Molecular Partners AG - Pipeline Products by Target 26
Molecular Partners AG - Pipeline Products by Route of Administration 27
Molecular Partners AG - Pipeline Products by Molecule Type 28
Molecular Partners AG - Pipeline Products by Mechanism of Action 29
Molecular Partners AG - Locations And Subsidiaries 30
Head Office 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32
List of Tables
Molecular Partners AG, Key Information 5
Molecular Partners AG, Key Facts 5
Molecular Partners AG - Pipeline by Indication, 2014 7
Molecular Partners AG - Pipeline by Stage of Development, 2014 8
Molecular Partners AG - Monotherapy Products in Pipeline, 2014 9
Molecular Partners AG - Out-Licensed Products in Pipeline, 2014 10
Molecular Partners AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 11
Molecular Partners AG - Phase I, 2014 12
Molecular Partners AG - Preclinical, 2014 13
Molecular Partners AG - Discovery, 2014 14
Molecular Partners AG - Pipeline by Target, 2014 26
Molecular Partners AG - Pipeline by Route of Administration, 2014 27
Molecular Partners AG - Pipeline by Molecule Type, 2014 28
Molecular Partners AG - Pipeline Products by Mechanism of Action, 2014 29 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify